http://ipkitten.blogspot.com/2023/08/life-sciences-strategy-summit-on-ip.html

Kat summit

The IPKat is pleased to inform readers that this year’s Life Sciences Strategy Summit on IP & Exclusivity will be held on 9, 10, 11 October 2023 in Munich (Germany).

This year’s summit follows the launch of the Unified Patent Court (UPC) and will inter alia allow participants to understand the industry’s reaction to the new court system and have candid discussions with European life science intellectual property experts.
As stated by the organizers, the highlights of this year’s edition are as follows:
  • Cross-industry end-user panel discussing the opening of the UPC and the life science industry response with Chr. Hansen and IFF alongside a judicial perspective with 4 legal judges and 3 technical judges
  • IP Minds Roundtable discussions on: Antibody Case Law, Biosimilar IP Considerations, Arrow Declaration, Clinical Trials and Patent Strategy, AI and Life Science Patents, Trade Secrets vs Patent Protection, FTO: Best Practices
  • 1-day dedicated event on SPCs entitled: Global SPC & PTE Forum 2023 with speakers from the European Commission, a Pan-European Patent Office Panel, the EPO, MSD, Polpharma Group and Adalvo
  • Building a practical Exclusivity Strategy and understanding the upcoming changes from the European Commission with speakers from Venable, Alkermes, Pieris Pharmaceuticals, BioNTech and Adalvo
The agenda can be accessed here, while the list of speakers is here.
New to this year’s edition is also the Global SPC & PTE Forum 2023, a one-day event dedicated to the key legislative changes and case law regarding SPC and PTE protection in Europe and beyond.
Readers can also watch this video interview with Thomas Böhmer, Head of IP at Pieris Pharmaceuticals, for a glimpse into his work and the topics that will be covered in October.
The IPKat has also negotiated a special discount for readers. To save 10% please use VIP code IPKAT at checkout. For more information and to register, please click here.

Content reproduced from The IPKat as permitted under the Creative Commons Licence (UK).